bluebird bio, Inc. (BLUE)

6.11 -0.17 (-2.71%) At close: 04:00PM EST

bluebird bio, Inc.

60 Binney Street
Cambridge, MA 02142
United States
339 499 9300
https://www.bluebirdbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 518

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Andrew Obenshain	Pres, CEO & Director	842.85k	N/A	1975
Mr. Thomas J. Klima	Chief Commercial Officer & COO	509.7k	N/A	1972
Ms. Katherine Edna Breedis C.F.A., CMT	Interim CFO, Principal Financial Officer & Principal Accounting Officer	N/A	N/A	1963
Ms. Jessica Whitten	VP, Global Controller & Chief Accounting Officer	N/A	N/A	1977
Ms. Elizabeth Pingpank	Director of Corp. Communications	N/A	N/A	N/A
Sarah Alspach	Chief Communications Officer	N/A	N/A	N/A
Ms. Andrea Walton	Chief People Officer	N/A	N/A	N/A
Dr. Liviu Niculescu M.D., Ph.D.	Sr. VP of Global Medical Affairs	N/A	N/A	N/A
Ms. Melissa Bonner	Sr. VP of Research	N/A	N/A	N/A
Mr. Richard Colvin M.D., Ph.D.	Chief Medical Officer	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Corporate governance

bluebird bio, Inc.’s ISS governance QualityScore as of 1 October 2022 is 7. The pillar scores are Audit: 9; Board: 7; Shareholder rights: 5; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.